Zachary Yablon, MD
Nephrology · Fort Lauderdale, FLNPI 1679772396
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.0% of the total across 433 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 30 manufacturers reported payments, led by AstraZeneca at 27.2% of the total. Among nephrology clinicians in FL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 433 payments — averaging $20.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- Amgen$1K
- Mallinckrodt Hospital Products Inc.$943
- OPKO Pharmaceuticals, LLC$715
- Bayer$555
- Vifor Pharma, Inc.$353
- plus $3K from 24 others
Across 96 payments — averaging $17,766 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Astrazeneca UK Limited$477K
- Boehringer Ingelheim$466K
- GSK$398K
- AstraZeneca$218K
- Eli Lilly$102K
- Merck$33K
- plus $11K from 2 others
What the payments were for
- Food & beverage$8,81097%
- Education$2713%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 123 | $2,471 |
| Amgen(2 entities) | 75 | $1,252 |
| Mallinckrodt Hospital Products Inc. | 43 | $943 |
| OPKO Pharmaceuticals, LLC | 32 | $715 |
| Bayer | 23 | $555 |
| Vifor Pharma, Inc. | 18 | $353 |
| Otsuka America Pharmaceutical, Inc. | 17 | $344 |
| Calliditas Therapeutics US Inc. | 12 | $328 |
| Travere Therapeutics, Inc. | 10 | $328 |
| GSK | 12 | $275 |
| Akebia Therapeutics Inc | 12 | $264 |
| Boehringer Ingelheim | 12 | $256 |
| ANI Pharmaceuticals, Inc. | 9 | $229 |
| Aurinia Pharma U.S., Inc. | 8 | $174 |
| Novo Nordisk | 4 | $72 |
| Outset Medical Inc | 1 | $72 |
| Novartis | 3 | $58 |
| Mallinckrodt Enterprises LLC | 2 | $52 |
| Kyowa Kirin, Inc. | 2 | $48 |
| Fresenius USA Marketing, Inc. | 3 | $46 |
| Baxter Healthcare | 2 | $42 |
| Shire North American Group Inc | 2 | $40 |
| Alnylam Pharmaceuticals Inc. | 1 | $28 |
| Ultragenyx Pharmaceutical Inc. | 1 | $24 |
| Ardelyx, Inc. | 1 | $23 |
| Sanofi | 1 | $22 |
| Shield Therapeutics Inc | 1 | $19 |
| La Jolla Pharmaceutical Company | 1 | $18 |
| Cumberland Pharmaceuticals, Inc. | 1 | $17 |
| Cormedix Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,081 in reported general payments places this provider in the 90th percentile of 756 nephrology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 416 | $409,690 |
| JardianceEmpagliflozin | 181 | $191,783 |
| KerendiaFinerenone | 142 | $167,377 |
| LokelmaSodium Zirconium Cyclosilicate | 31 | $51,724 |
| OzempicSemaglutide | 19 | $28,903 |
| VeltassaPatiromer Calcium Sorbitex | 15 | $26,142 |
| Cinacalcet Hcl | 33 | $6,435 |
| Sevelamer Carbonate | 13 | $2,910 |
| Calcitriol | 109 | $2,101 |
| Losartan Potassium | 185 | $1,366 |
| Nifedipine ErNifedipine | 38 | $1,192 |
| Lisinopril | 114 | $907 |
| Amlodipine Besylate | 105 | $851 |
| Hydralazine Hcl | 47 | $771 |
| Vitamin D2Ergocalciferol (Vitamin D2) | 59 | $505 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Lokelma | $2,471 | $461,414447 claims |
| Boehringer IngelheimJardiance | $256 | $191,783181 claims |
| BayerKerendia | $555 | $167,377142 claims |
| Novo NordiskOzempic | $72 | $28,90319 claims |
| ANI Pharmaceuticals, Inc.Valsartan | $229 | $30715 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 756 nephrology providers in Florida.
Other nephrology in Fort Lauderdale
- Carlos BejarFort Lauderdale$530K
- Wayne KotzkerFort Lauderdale$472K
- Rafael Baez BonillaFort Lauderdale$175K
- Reinaldo RosarioFort Lauderdale$75K
- Parham EftekhariFort Lauderdale$22K
- Arvind MadanOrlando$943K
- John CopleyWeston$934K
- Jorge LarranagaKissimmee$825K
- Jason RothschildTemple Terrace$413K
- Daniel PatelDaytona Beach$227K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.